



## **ABILITA BIO TO SHOWCASE ENABLED MEMBRANE PROTEIN TECHNOLOGIES AT PEGS BOSTON CONFERENCE**

***On the Heels of a \$7.5M Financing Round, the Company will Present its Breakthrough Platform Technologies that are Empowering the Development of Membrane Protein-Targeted Treatments***

San Diego, California, May 9, 2023 — Abilita Bio, a leader in discovering and developing membrane protein-targeted therapeutics, announced today that it will present at the prestigious PEGS Boston conference held May 15-19, 2023. The meeting, widely regarded as one of the leading protein and antibody engineering events, will be held at the Hynes Convention Center in Boston, Massachusetts. More information about the event can be found on the conference website: <https://www.pegsummit.com/>.

This announcement follows Abilita Bio's recent \$7.5M equity financing round led by Two Bear Capital. The funds will be used to accelerate the company's existing preclinical therapeutic programs, initiate new efforts on additional targets, and to expand its operations in San Diego. Abilita Bio is leveraging its innovative suite of Enabled Membrane Protein (EMP™) technologies to overcome critical technical hurdles in developing therapeutics for challenging membrane protein targets.

At PEGS Boston, Abilita Bio will showcase its cutting-edge EMP platform and share insights into its current pipeline of therapeutic antibody programs. The company aims to bridge the massive technology gap in the membrane protein space, which has hindered the development of effective therapeutics for many years. Abilita Bio is focused on moving its first asset toward the clinical development candidate stage and building partnerships with industry leaders across biologics and small molecules.

### **About Abilita Bio**

Abilita Bio, Inc. is a privately held, innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically important multi-span membrane proteins. Abilita Bio's validated drug discovery engine builds on the foundation of its powerful EMP™ target evolution platform and deep membrane protein expertise to a suite of internal antibody discovery technologies. For more information, visit [www.abilitabio.com](http://www.abilitabio.com).